Pelthos Therapeutics Inc (PTHS) Stock AnalysisPTHSStock AnalysisPelthos Therapeutics Inc

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older. It operates in the Healthcare sector.

Pelthos Therapeutics Inc is not a good buy right now due to its current price of $24.73, which is significantly below the lowest analyst price target of $45, indicating a potential downside. Additionally, the RSI of 31.416 suggests that the stock is oversold, but the negative earnings report with an EPS of -6.62 raises concerns about its financial health. The main risk is the company's high net loss of $23.4 million in Q2 2026, which could impact future growth prospects.